Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.41 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.41 |
| ▸ | RIOK1 | Q9BRS2 | 1/20 | 0.41 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.41 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16793852 | 0.92 | BTK (0.47) | BTKAAK1JAK2CYP3A4HRH2 | |
| SCHEMBL20027003 | 0.81 | BTK (0.45) | BTKAAK1JAK2CYP3A4HRH2 | |
| SCHEMBL25176701 | 0.76 | ROCK1 (0.40) | BTKAAK1JAK2CYP3A4HRH2 | |
| SCHEMBL16794462 | 0.74 | NPC1 (0.43) | AAK1ROCK1HIF1AEPHX2PRMT5 | |
| SCHEMBL18183911 | 0.74 | BTK (0.48) | BTKAAK1JAK2CYP3A4HRH2 | |
| SCHEMBL18183922 | 0.73 | BTK (0.54) | BTKROCK1EPHX2PRMT5WDR77 | |
| SCHEMBL29547987 | 0.72 | NPC1 (0.41) | AAK1ROCK1HIF1APRMT5WDR77 | |
| SCHEMBL24270172 | 0.72 | NPC1 (0.41) | AAK1ROCK1HIF1APRMT5WDR77 | |
| SCHEMBL16793564 | 0.71 | BTK (0.53) | BTKAAK1JAK2CYP3A4HRH2 | |
| SCHEMBL25590604 | 0.71 | BTK (0.53) | BTKAAK1JAK2CYP3A4HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885AAK1 455/4885JAK2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.